ClinicalTrials.gg
Drug

Gefapixant clinical trials

Also written MK-7264 and AF-219.

studies test it
27
open now
2
in phase 3
6
first study started
2011

How each study uses Gefapixant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Gefapixant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
15 Sept 2023 · Lyfnua · EMEA/H/C/005476 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Gefapixant
21
Gefapixant 15 mg BID
2
Gefapixant 45 mg BID
2

Development codes

MK-7264
25
AF-219
14

Studies by the year they started

27 studies that test it; most in 2015 (8)

Studies that test Gefapixant, by start year
YearStudies
20111
20122
20131
20141
20158
20161
20171
20186
20192
20202
20242

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
5
Phase 2
14
Phase 3
6
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 25 · Other 2

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (14) · Merck Sharp & Dohme LLC (11) · Nagoya City University (1) · Stuart Mazzone (1)

Studies

Open first, then newest update. How each study uses Gefapixant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 27

See all 27 studies that test Gefapixant →

Codes

What other systems call Gefapixant · ClinicalTrials.gg INT000214

  • MeSH (NLM) C000597312GefapixantOne source NLM
  • UNII (FDA) 6K6L7E3F1LGEFAPIXANTConfirmed FDA, NLM, Wikidata
  • Wikidata Q94572860gefapixantConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C166945GefapixantOne source FDA
  • DrugBank DB15097One source Wikidata

Also registered as gefapixant citrate (UNII DFK0FC2VVV).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.